nach oben

04.05.2024 | Original Article

Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers

verfasst von: Pengfei Du, Yao Long, Minhui Wang, Yunzhe Huang, Yaqin Wang, Xinyan Chen, Yuhong Lin, Jianbang Wu, Jie Shen, Yuanwei Jia

Erschienen in: Cancer Chemotherapy and Pharmacology

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study assessed effect of food on pharmacokinetics (PK) and safety of fuzuloparib capsules.

Methods

A randomized, open-label, two-cycle, two-sequence, crossover clinical trial was conducted. 20 subjects were randomly assigned to 2 groups at a 1:1 ratio. The first group subjects were orally administered 150 mg fuzuloparib capsules under fasting condition in first dosing cycle. The same dose of fuzuloparib capsules were taken under postprandial state after a 7-day washout period. The second group was reversed. 3 ml whole blood was collected at each blood collection point until 72 h post dose. PK parameters were calculated. Furthermore, safety assessment was performed.

Results

The time to maximum concentration (T_max) was prolonged to 3 h and maximum concentration (C_max) decreased by 18.6% on high-fat diets. 90% confidence intervals (CIs) of geometric mean ratios (GMRs) for C_max, area under the concentration–time curve from time zero to time t (AUC_0−t), and area under the concentration–time curve extrapolated to infinity (AUC_0−∞) after high-fat meal were 71.6–92.6%, 81.7–102.7% and 81.6–102.5%, respectively. All treatment-emergent adverse events (TEAEs) were grade 1; No serious adverse events (SAEs), serious unexpected suspected adverse reaction (SUSAR) or deaths were reported.

Conclusion

Food decreased the absorption rate and slowed time to peak exposure of fuzuloparib capsules, without impact on absorption extent. Dosing with food was found to be safe for fuzuloparib capsules in this study.

Clinical trial registration.

This study was registered with chinadrugtrials.org.cn (identifier: CTR20221498).

Nur mit Berechtigung zugänglich

Kamel D, Gray C, Walia JS, Kumar V (2018) PARP inhibitor drugs in the treatment of breast, ovarian, prostate and pancreatic cancers: an update of clinical trials. Curr Drug Target. https://doi.org/10.2174/1389450118666170711151518CrossRef

Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A (2016) PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Menopausal Rev 4:215–219. https://doi.org/10.5114/pm.2016.65667CrossRef

Thomas C, Tulin AV (2013) Poly-ADP-ribose polymerase: machinery for nuclear processes. Mol Aspects Med 34(6):1124–1137. https://doi.org/10.1016/j.mam.2013.04.001CrossRefPubMed

D’Andrea AD (2018) Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair 71:172–176. https://doi.org/10.1016/j.dnarep.2018.08.021CrossRefPubMed

Cortesi L, Rugo HS, Jackisch C (2021) An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol 16(3):255–282. https://doi.org/10.1007/s11523-021-00796-4CrossRefPubMedPubMedCentral

Slade D (2020) PARP and PARG inhibitors in cancer treatment. Genes Dev 34(5–6):360–394. https://doi.org/10.1101/gad.334516.119CrossRefPubMedPubMedCentral

Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18(9):1274–1284. https://doi.org/10.1016/s1470-2045(17)30469-2CrossRefPubMed

Monk BJ, Parkinson C, Lim MC et al (2022) A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 40(34):3952–3964. https://doi.org/10.1200/jco.22.01003CrossRefPubMedPubMedCentral

Lee A (2021) Fuzuloparib: first approval. Drugs 81(10):1221–1226. https://doi.org/10.1007/s40265-021-01541-xCrossRefPubMedPubMedCentral

10.

Li N, Bu H, Liu J et al (2021) An open-label, multicenter, single-arm, phase II study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer. Clin Cancer Res 27(9):2452–2458. https://doi.org/10.1158/1078-0432.Ccr-20-3546CrossRefPubMed

11.

Li N, Zhang Y, Wang J et al (2022) Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. J Clin Oncol 40(22):2436–2446. https://doi.org/10.1200/jco.21.01511CrossRefPubMed

12.

Li N, Liu Q, Tian Y, Wu L (2022) Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective. J Gynecol Oncol. https://doi.org/10.3802/jgo.2022.33.e86CrossRefPubMedPubMedCentral

13.

Wu Y, Zhang X, Li L et al (2022) Case report and review of literature: camrelizumab combined with fuzuloparib and apatinib for platinum-resistant recurrent ovarian cancer. Onco Targets Ther 15:973–979. https://doi.org/10.2147/ott.S375643CrossRefPubMedPubMedCentral

14.

Luo J, Dai X, Hu H et al (2019) Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. J Cancer Res Clin Oncol 146(3):721–737. https://doi.org/10.1007/s00432-019-03097-6CrossRefPubMed

15.

Xu Y, Huang Z, Fang J et al (2022) Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial. Transl Lung Cancer Res 11(6):1069–1078. https://doi.org/10.21037/tlcr-22-356CrossRefPubMedPubMedCentral

16.

U.S. National Library of Medicine (2020) A study of fluzoparib in combination with mFOLFIRINOX in patients with resectable pancreatic cancer. https://classic.clinicaltrials.gov/ct2/show/NCT04425876?term=NCT04425876&draw=2&rank=1. Accessed 24 May 2023

17.

U.S. National Library of Medicine (2022) Fluzoparib in combination with chidamide or camrelizumab for HRD positive HER2 negative advanced breast cancer. https://classic.clinicaltrials.gov/ct2/show/NCT05085626?term=NCT05085626&draw=2&rank=1. Accessed 24 May 2023

18.

U.S. National Library of Medicine (2022) A non-interventional registry study of fluzoparib in the treatment of ovarian cancer. https://classic.clinicaltrials.gov/ct2/show/NCT05206890?term=Fluzoparib&draw=2&rank=2. Accessed 24 May 2023

19.

Li H, Liu R, Shao B et al (2020) Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chin J Cancer Res 32(3):370–382. https://doi.org/10.21147/j.issn.1000-9604.2020.03.08CrossRefPubMedPubMedCentral

20.

Bian Y, Meng J, Ma S et al (2022) Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers. Br J Clin Pharmacol 88(7):3307–3320. https://doi.org/10.1111/bcp.15256CrossRefPubMed

21.

Huang Y, Jia Y, Chen X et al (2023) CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study. Expert Opin Drug Metab Toxicol 19(12):1005–1013. https://doi.org/10.1080/17425255.2023.2292112CrossRefPubMed

22.

Huang Y, Liu R, Wang Y et al (2022) Evaluation of pharmacokinetic interactions between the new SGLT2 inhibitor SHR3824 and Valsartan in healthy Chinese volunteers. Clin Ther 44(7):945–956. https://doi.org/10.1016/j.clinthera.2022.06.001CrossRefPubMed

23.

He X, Liu G, Chen X et al (2023) Pharmacokinetic and pharmacodynamic interactions between Henagliflozin, a novel selective SGLT-2 inhibitor, and Warfarin in healthy Chinese subjects. Clin Ther 45(7):655–661. https://doi.org/10.1016/j.clinthera.2023.06.002CrossRefPubMed

24.

Hu C, Zhang Y, Pei T, Liu P, Zhang L (2023) Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers. Cancer Chemother Pharmacol 91(6):523–529. https://doi.org/10.1007/s00280-023-04536-5CrossRefPubMed

25.

Hu L, Dou T, Sun Q et al (2023) Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: an open-label, fixed sequence study in Chinese healthy male subjects. Invest New Drugs 41(2):276–283. https://doi.org/10.1007/s10637-023-01331-0CrossRefPubMed

26.

Wu M, Li X, Sun J, Chen H, Ding Y (2021) A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism afteroral dosing in healthy Chinese volunteers. Expert Opin Drug Metab Toxicol 17(4):503–508. https://doi.org/10.1080/17425255.2021.1881480CrossRefPubMed

27.

Jiang X, Tao Y, Liu Y et al (2021) A randomized, open-label, two-period crossover bridging study on fuzuloparib capsules of different specifications in healthy Chinese volunteers. Br J Clin Pharmacol 88(3):1087–1093. https://doi.org/10.1111/bcp.15035CrossRefPubMed

28.

U.S. Food & Drug Administration (2022) Assessing the effects of food on drugs in INDs and NDAs—clinical pharmacology considerations. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-effects-food-drugs-inds-and-ndas-clinical-pharmacology-considerations. Accessed 24 May 2023

29.

World Medical Association (2013) WMA declaration of helsinki-ethical principles for medical research involving human subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed 24 May 2023

30.

Committee for Medicinal Products for Human Use in European Medicines Agency, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2016) Guideline for good clinical practice E6(R2). https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf. Accessed 24 May 2023

31.

Plummer R, Swaisland H, Leunen K et al (2015) Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemother Pharmacol 76(4):723–729. https://doi.org/10.1007/s00280-015-2836-2CrossRefPubMed

32.

Moore K, Zhang Z-Y, Agarwal S, Burris H, Patel MR, Kansra V (2018) The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol 81(3):497–503. https://doi.org/10.1007/s00280-017-3512-5CrossRefPubMed

33.

Shapiro GI, Kristeleit RS, Burris HA et al (2018) Pharmacokinetic study of rucaparib in patients with advanced solid tumors. Clin Pharmacol Drug Dev 8(1):107–118. https://doi.org/10.1002/cpdd.575CrossRefPubMedPubMedCentral

34.

Rolfo C, Swaisland H, Leunen K et al (2015) Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv Ther 32(6):510–522. https://doi.org/10.1007/s12325-015-0214-4CrossRefPubMed

35.

Bruin MAC, Sonke GS, Beijnen JH, Huitema ADR (2022) Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin Pharmacokinet 61(12):1649–1675. https://doi.org/10.1007/s40262-022-01167-6CrossRefPubMedPubMedCentral

36.

Ledermann J, Harter P, Gourley C et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15(8):852–861. https://doi.org/10.1016/s1470-2045(14)70228-1CrossRefPubMed

Titel: Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers
verfasst von: Pengfei Du
Yao Long
Minhui Wang
Yunzhe Huang
Yaqin Wang
Xinyan Chen
Yuhong Lin
Jianbang Wu
Jie Shen
Yuanwei Jia
Publikationsdatum: 04.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-024-04672-6

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers

Abstract

Purpose

Methods

Results

Conclusion

Clinical trial registration.

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Clinical trial registration.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie